IMUNON, Inc. announced on July 28, 2025, that its Board of Directors approved a 15% stock dividend, distributing 0.15 shares of common stock for each share of common stock and common stock equivalent with dividend rights. This stock grant reflects the company’s confidence in its clinical programs, long-term growth strategy, and dedication to rewarding shareholders.
Approximately 448,000 additional shares of IMUNON common stock will be distributed through this program. The dividend is payable to holders of record as of August 7, 2025, with the distribution expected to occur on August 21, 2025.
Shareholders will not be required to take any action to receive the dividend, as their book entry accounts will be credited with the additional shares. This action underscores IMUNON's commitment to creating value while advancing its innovative pipeline, including the lead IMNN-001 program in advanced ovarian cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.